| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $32.0M | — | -36.2% |
| SG&A Expense | $14.1M | — | -6.0% |
| Operating Income | -$46.1M | — | +29.3% |
| Net Income | -$42.6M | — | +28.7% |
| EPS (Basic) | -$0.18 | — | +35.7% |
| EPS (Diluted) | -$0.18 | — | +35.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $30.3M | -41.4% | -28.6% |
| Current Assets | $273.3M | +6.0% | -6.3% |
| Total Assets | $396.0M | -4.8% | -22.1% |
| Current Liabilities | $28.3M | -12.9% | -5.6% |
| Total Liabilities | $117.1M | -5.1% | -4.5% |
| Stockholders' Equity | $278.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.9M | — | +75.6% |
| Capital Expenditures | $9K | — | -90.9% |
| Investing Cash Flow | -$29.6M | — | -579.1% |
| Financing Cash Flow | $21.1M | — | +51.0% |
| Free Cash Flow | -$12.9M | — | +75.6% |
| -27.6% |